Testicular cancer medical therapy

Revision as of 21:46, 16 October 2015 by Shanshan Cen (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Testicular cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Testicular cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Testicular cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Testicular cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Testicular cancer medical therapy

CDC on Testicular cancer medical therapy

Testicular cancer medical therapy in the news

Blogs on Testicular cancer medical therapy

Directions to Hospitals Treating Testicular cancer

Risk calculators and risk factors for Testicular cancer medical therapy

Overview

Medical Therapy

Radiation therapy

  • Radiation therapy works best for seminomas. Non-seminomas do not respond well to radiation therapy.
  • External beam radiation may be used for stage I and II seminomas after surgery to remove the testicle (called orchiectomy).
  • Radiation treatments are usually given once a day, 5 days a week, for 2–4 weeks.

Chemotherapy

Standard-dose chemotherapy

  • The most common chemotherapy combinations used to treat testicular cancer are:
  • BEP is bleomycin (Blenoxane), etoposide (Vepesid, VP-16) and cisplatin (Platinol AQ). It is usually given through a needle in a vein (intravenously) every 3 weeks for 2–3 months, or 3 or 4 cycles. In some cases, 1 or 2 cycles of BEP may be given for stage I non-seminomas.
  • EP is etoposide and cisplatin. EP is used when bleomycin affects the lungs (called pulmonary toxicity) or there is a high risk that it will cause lung damage. It is given intravenously every 3 weeks for 3 months, or 4 cycles.
  • VIP is etoposide, ifosfamide (Ifex) and cisplatin. VIP may be used when bleomycin affects the lungs (called pulmonary toxicity) or there is a high risk that it will cause lung damage. It is given intravenously every 3 weeks for 3 months, or 4 cycles.
  • If testicular cancer doesn’t respond to the above drugs or if it recurs, the following chemotherapy combinations may be used. These are sometimes called salvage, or second-line, chemotherapy.
  • TIP is paclitaxel (Taxol), ifosfamide and cisplatin. It is given intravenously every 3 weeks for 3 months, or 4 cycles.
  • VIP is etoposide, ifosfamide and cisplatin. It is given intravenously every 3 weeks for 3 months, or 4 cycles.
  • VeIP is etoposide or vinblastine (Velbe), ifosfamide and cisplatin. It is given intravenously every 3 weeks for 3 months, or 4 cycles.

High-dose chemotherapy

  • High-dose chemotherapy with carboplatin and etoposide may be used if testicular cancer recurs after it is treated with standard-dose chemotherapy.

Palliative chemotherapy

  • Palliative therapy is given to relieve symptoms, rather than to treat the cancer itself. Gemcitabine (Gemzar) may be given with oxaliplatin (Eloxatin), paclitaxel or both as palliative treatment for seminomas or non-seminomas. Etoposide taken by mouth (orally) is also an option for palliative chemotherapy.

References


Template:WikiDoc Sources